Inactive Instrument

PREDILIFE Share Price Euronext Paris

ALPRE

FR0010169920

Biotechnology & Medical Research

End-of-day quote Euronext Paris Other stock markets
-	-

06-28	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-09	Intégrance Launches Preventive Health Program for Employees

News in other languages: PREDILIFE

07-16	Predilife : Bilan semestriel au 30/06/2026 du contrat de liquidité PREDILIFE
07-02	Predilife : RÉSILIATION DU CONTRAT DE LIQUIDITÉ CONCLU AVEC TSAF
07-01	Predilife : RÉSULTATS DE L’ASSEMBLÉE GÉNÉRALE ORDINAIRE ET EXTRAORDINAIRE
06-30	Un trimestre boursier exubérant, mais pas irrationnel ?
06-29	Predilife : PREDILIFE POINT CONCERNANT LA FDA ET MISE A DISPOSITION DU RAPPORT FINANCIER ANNUEL 2025

More news

Managers and Directors: PREDILIFE

Manager	Title	Age	Since
Stéphane Ragusa CEO	Chief Executive Officer	56	31/12/2003
Émilien Gauthier CTO	Chief Tech/Sci/R&D Officer	-	31/12/2006
Marion Renelier LAW	General Counsel	-	31/12/2015

Director	Title	Age	Since
Stéphane Ragusa CHM	Chairman	56	31/12/2003
Charles Vilgrain BRD	Director/Board Member	46	31/12/2017
Antoine Bricard BRD	Director/Board Member	58	31/12/2017

More insiders

PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.

Employees

Sector

Biotechnology & Medical Research

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	4.14M 0 4.73M 3.85M 3.54M 6.66M 457M 6.76M 45.86M 17.92M 223M 17.74M 17.36M 771M	P/E 2024	-3.18x	P/E 2025	-3.01x
Enterprise Value	8.92M 0 10.18M 8.29M 7.61M 14.33M 983M 14.56M 98.74M 38.58M 480M 38.2M 37.38M 1.66B	EV / Sales 2024	34.5x	EV / Sales 2025	19.3x
Free-Float	48.75%	Yield 2024 *	-	Yield 2025	-

06-28	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-09	Intégrance Launches Preventive Health Program for Employees
09/10/25	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
02/07/25	Predilife S.A. announced a financing transaction	CI
05/06/25	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
09/04/25	Edil San Felice Bags EUR16 Million Maintenance Works Contract in Italy	MT
23/04/24	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
04/09/23	Predilife: a project accredited by Finance Innovation
14/07/23	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI
27/04/23	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	CI
12/04/23	Predilife: predictive assessment contract with Colas
28/10/22	Predilife S.A. Reports Earnings Results for the Half Year Ended June 30, 2022	CI
25/04/22	Predilife S.A. Reports Earnings Results for the Full Year Ended December 31, 2021	CI

24/10/25	PREDILIFE : MISE A DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2025	PU
09/10/25	PREDILIFE : RESULTATS SEMESTRIELS 2025	PU
29/05/24	Predilife : PREDILIFE STRENGTHENS ITS ASSETS WITH THE ISSUANCE OF A PATENT FOR ITS AI METHOD	AT
01/05/24	Predilife : IN EXTENSO FINANCE UPDATES COVERAGE ON PREDILIFE STOCK; TARGET PRICE OF EUR 25.07 REPRESENTS +391% POTENTIAL UPSIDE	AT
25/04/24	Predilife : Valuation of MammoRisk(R) software	AT

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXACT SCIENCES CORPORATION	+0.95%	-.--%	+116.94%	+10.40%	20.03B
VERACYTE, INC.	-2.55%	+2.45%	+151.89%	+102.97%	4.75B
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-2.79%	+2.43%	+112.90%	+171.66%	3.61B
IOVANCE BIOTHERAPEUTICS, INC.	-5.66%	+31.55%	+107.63%	-32.59%	2.45B
BGI GENOMICS CO., LTD.	+2.01%	+3.82%	-26.08%	-35.34%	2.08B
CAREDX, INC.	-1.97%	+30.59%	+196.31%	+255.41%	1.99B
MARAVAI LIFESCIENCES HOLDINGS, INC.	0.00%	+9.06%	+198.32%	-43.20%	1.05B
SEEGENE, INC.	-1.10%	-2.71%	-13.50%	+25.12%	837M
HANGZHOU ALLTEST BIOTECH CO., LTD.	-0.14%	+1.86%	-36.72%	-14.16%	495M
Average	-1.25%	+8.34%	+89.74%	+48.92%	4.14B
Weighted average by Cap.	-0.48%	+5.43%	+113.96%	+44.02%

	2024	2025
Net sales	493K 0 563K 458K 421K 792K 54.35M 805K 5.46M 2.13M 26.55M 2.11M 2.07M 91.75M	836K 0 953K 777K 713K 1.34M 92.1M 1.36M 9.25M 3.61M 45M 3.58M 3.5M 155M
Net income	-4.26M -0 -4.86M -3.96M -3.64M -6.85M -470M -6.96M -47.2M -18.44M -230M -18.26M -17.87M -793M	-3.93M -0 -4.49M -3.66M -3.36M -6.32M -434M -6.42M -43.55M -17.02M -212M -16.85M -16.48M -732M
Net Debt	3.54M 0 4.04M 3.29M 3.02M 5.69M 390M 5.78M 39.16M 15.3M 191M 15.15M 14.82M 658M	4.78M 0 5.45M 4.44M 4.08M 7.68M 526M 7.8M 52.88M 20.66M 257M 20.46M 20.02M 889M

PREDILIFE Share Price Euronext Paris

Stocks

ALPRE

FR0010169920

Biotechnology & Medical Research

Valuation: PREDILIFE

Latest news : PREDILIFE

Press Releases: PREDILIFE

News in other languages: PREDILIFE

Managers and Directors: PREDILIFE

Bio Diagnostics & Testing

Financials

Company Profile